Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1141 AL 1155

Dopaminergic Signaling as a Plausible Modulator of Astrocytic Toll-Like Receptor 4: A Crosstalk between Neuroinflammation and Cognition

Gurram PC, Manandhar S, Satarker S, Mudgal J, Arora D, Nampoothiri M.

CNS Neurol Disord Drug Targets. 2023;22(4):539-557. doi: 10.2174/1871527321666220413090541.

The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimer's Disease

Wang Y.

CNS Neurol Disord Drug Targets. 2023;22(4):577-598. doi: 10.2174/1871527321666220417005115.

Therapeutic Effects of Thymoquinone on Alzheimer's Disease through Modulating Amyloid-beta Neurotoxicity and Neuro-inflammatory Cytokine Levels

Alasmari F, Alotaibi FM, Al-Qahtani WS, AlAsmari AF, Alqahtani F.

CNS Neurol Disord Drug Targets. 2023;22(5):736-744. doi: 10.2174/1871527321666220418125057.

Current Trends in the Animal Models for Screening of Nootropic Agents: A Systematic Review

Grover S, Jain S.

Curr Rev Clin Exp Pharmacol. 2023;18(3):255-269. doi: 10.2174/2772432817666220425121323.

Berberine: Is it a Promising Agent for Mental Disorders Treatment?

Shayganfard M.

Curr Mol Pharmacol. 2023;16(3):307-320. doi: 10.2174/1874467215666220509213122.

The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease

Ravikumar M, Mohan S, Velpandian C.

Curr Drug Saf. 2023;18(3):284-296. doi: 10.2174/1574886317666220517125644.

Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease

Sharma P, Babbar R, Sharma T, Madaan P, Arora S, Badavath VN.

Mini Rev Med Chem. 2023;23(1):53-66. doi: 10.2174/1389557522666220524090354.

Amyloid Beta Peptide-Mediated Alterations in Mitochondrial Dynamics and its Implications for Alzheimer's Disease

Monsalvo-Maraver LÁ, Maya-López M, Rangel-López E, Túnez I, Tinkov AA, Skalny A, Ferrer B, Aschner M, Santamaría A.

CNS Neurol Disord Drug Targets. 2023;22(7):1039-1056. doi: 10.2174/1871527321666220616094036.

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease

de Souza MM, Cenci AR, Teixeira KF, Machado V, Mendes Schuler MCG, Gonçalves AE, Paula Dalmagro A, André Cazarin C, Gomes Ferreira LL, de Oliveira AS, Andricopulo AD.

Curr Med Chem. 2023;30(6):669-688. doi: 10.2174/0929867329666220620162018.

Mechanistic and Etiological Similarities in Diabetes Mellitus and Alzheimer's Disease: Antidiabetic Drugs as Optimistic Therapeutics in Alzheimer's Disease

Das S, Ramachandran AK, Halder D, Akbar S, Ahmed B, Joseph A.

CNS Neurol Disord Drug Targets. 2023;22(7):973-993. doi: 10.2174/1871527321666220629162229.

Anticholinesterase Agents For Alzheimer's Disease Treatment: An Updated Overview

Llanes LC, Kuehlewein I, França IV, da Silva LV, da Cruz Junior JW.

Curr Med Chem. 2023;30(6):701-724. doi: 10.2174/0929867329666220803113411.

Genetic Causes of Alzheimer's Disease and the Neuroprotective Role of Melatonin in its Management

Sundram S, Malviya R, Awasthi R.

CNS Neurol Disord Drug Targets. 2023;22(9):1302-1312. doi: 10.2174/1871527321666220901125730.

Current Naturopathy to Combat Alzheimer's Disease

Chakrovorty A, Bhattacharjee B, Saxena A, Samadder A, Nandi S.

Curr Neuropharmacol. 2023;21(4):808-841. doi: 10.2174/1570159X20666220927121022.

Atorvastatin's Reduction of Alzheimer's Disease and Possible Alteration of Cognitive Function in Midlife as well as its Treatment

Shah U, Shah A, Patel S, Patel A, Patel M, Solanki N, Patel S, Patel A, Patel V, Patel B.

CNS Neurol Disord Drug Targets. 2023;22(10):1462-1471. doi: 10.2174/1871527322666221005124808.

Recent Advances in the Development of Nitrogen-containing Heterocyclic Anti-alzheimer's Agents

Kumar A, Nehra B, Singh D, Kumar D, Chawla PA.

Curr Top Med Chem. 2023;23(13):1277-1306. doi: 10.2174/1568026623666221019152502.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias